This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Aug;30(4):476-8.

doi: 10.1097/JCP.0b013e3181e5c168.

Reduced cannabis use after low-dose naltrexone addition to opioid detoxification

Paolo Mannelli, Kathi Peindl, Ashwin A Patkar, Li-Tzy Wu, Chi-Un Pae, David A Gorelick

PMID: 20631574
PMCID: PMC3091262
DOI: 10.1097/JCP.0b013e3181e5c168

Reduced cannabis use after low-dose naltrexone addition to opioid detoxification

Paolo Mannelli et al. J Clin Psychopharmacol. 2010 Aug.

. 2010 Aug;30(4):476-8.

doi: 10.1097/JCP.0b013e3181e5c168.

Authors

Paolo Mannelli, Kathi Peindl, Ashwin A Patkar, Li-Tzy Wu, Chi-Un Pae, David A Gorelick

PMID: 20631574
PMCID: PMC3091262
DOI: 10.1097/JCP.0b013e3181e5c168

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

No author has declared potential conflict of interest with the present work.

Similar articles

Early outcomes following low dose naltrexone enhancement of opioid detoxification.
Mannelli P, Patkar AA, Peindl K, Gottheil E, Wu LT, Gorelick DA. Mannelli P, et al. Am J Addict. 2009 Mar-Apr;18(2):109-16. doi: 10.1080/10550490902772785. Am J Addict. 2009. PMID: 19283561 Free PMC article. Clinical Trial.
Advances in opioid antagonist treatment for opioid addiction.
Ling W, Mooney L, Wu LT. Ling W, et al. Psychiatr Clin North Am. 2012 Jun;35(2):297-308. doi: 10.1016/j.psc.2012.03.002. Epub 2012 Apr 10. Psychiatr Clin North Am. 2012. PMID: 22640757 Free PMC article. No abstract available.
[Limited role of naltrexone in the treatment of opiate addiction].
van Brussel GH. van Brussel GH. Ned Tijdschr Geneeskd. 2001 Jul 28;145(30):1452-6. Ned Tijdschr Geneeskd. 2001. PMID: 11503313 Review. Dutch.
Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.
Raby WN, Carpenter KM, Rothenberg J, Brooks AC, Jiang H, Sullivan M, Bisaga A, Comer S, Nunes EV. Raby WN, et al. Am J Addict. 2009 Jul-Aug;18(4):301-8. doi: 10.1080/10550490902927785. Am J Addict. 2009. PMID: 19444734 Free PMC article. Clinical Trial.
[Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
Poser W, Ehrenreich H. Poser W, et al. Internist (Berl). 1996 Oct;37(10):1061-7; discussion 1067. Internist (Berl). 1996. PMID: 9019453 Review. German. No abstract available.

See all similar articles

Cited by

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives.
Tek C. Tek C. Patient Prefer Adherence. 2016 May 4;10:751-9. doi: 10.2147/PPA.S84778. eCollection 2016. Patient Prefer Adherence. 2016. PMID: 27217728 Free PMC article. Review.
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.
Mannelli P, Peindl KS, Lee T, Bhatia KS, Wu LT. Mannelli P, et al. Curr Drug Abuse Rev. 2012 Mar;5(1):52-63. doi: 10.2174/1874473711205010052. Curr Drug Abuse Rev. 2012. PMID: 22280332 Free PMC article. Review.
Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse.
Sushchyk S, Xi ZX, Wang JB. Sushchyk S, et al. J Pharmacol Exp Ther. 2016 May;357(2):248-57. doi: 10.1124/jpet.115.229542. Epub 2016 Feb 22. J Pharmacol Exp Ther. 2016. PMID: 26903543 Free PMC article.
Simultaneous Determination of Levo-tetrahydropalmatine and Naltrexone in Rat Plasma by LC-MS/MS and its Application in a Pharmacokinetic Study.
Feng K, Sy SKB, Yu M, Lv Z, Yan M. Feng K, et al. Curr Pharm Biotechnol. 2024;25(14):1875-1883. doi: 10.2174/0113892010271975231218074830. Curr Pharm Biotechnol. 2024. PMID: 38213152
Opioid antagonists with minimal sedation for opioid withdrawal.
Gowing L, Ali R, White JM. Gowing L, et al. Cochrane Database Syst Rev. 2017 May 29;5(5):CD002021. doi: 10.1002/14651858.CD002021.pub4. Cochrane Database Syst Rev. 2017. PMID: 28553701 Free PMC article.

References

1. Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction. 2003;98:269–279. - PMC - PubMed
1. Raby WN, Carpenter KM, Rothenberg J, et al. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict. 2009;18:301–308. - PMC - PubMed
1. Budney AJ, Roffman R, Stephens RS, et al. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4:4–16. - PMC - PubMed
1. Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology. 2007;32:1391–1403. - PubMed
1. Mannelli P, Patkar AA, Peindl K, et al. Early outcomes following low dose naltrexone enhancement of opioid detoxification. Am J Addict. 2009;18:109–116. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

Grants and funding

ImNIH/Intramural NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information